| A randomized study comparing oral and standard regimens for metastatic breast cancer |
Authors: Taisuke Hori, Hiroshi Kodama, Satoru Nishimura, Takehiko Hatano, Ryuji Okamura, Koji Fujii, Takashi Kudo, Takashi Inamoto, Kiyoshi Sawai, Masao Kobayashi, Hiroki Ogawa, Norio Yoshimura, Masahiro Hiraoka |
Affiliations:
Department of Surgery, Kyoto Police Hospital, Kita-ku, Kyoto 603-8142, Japan
|
Pages: 1067-1071 |
Abstract:
We conducted a randomized controlled trial comparing oral regimen [doxifluridine, an intermediate metabolite of capecitabine, + medroxyprogesterone acetate (MPA) + cyclophosphamide (CPA)] (Method A) with a standard regimen (5-fluorouracil + adriamycin + CPA) plus MPA (Method B) as first line chemotherapy for metastatic breast cancer. Overall response rate was 55.8% for Method A, 46.3% for Method B. The total ratio of responder and long stable disease was significantly higher with Method A (p=0.006). Median time to progression and survival were not differences between Methods. Incidence of toxicity was 56.3% with Method A and 80.0% with Method B (p=0.014). Oral regimen is more useful than standard therapy.
|
|
|
|
|
